Literature DB >> 29431732

STAT3/p53 pathway activation disrupts IFN-β-induced dormancy in tumor-repopulating cells.

Yuying Liu1,2, Jiadi Lv1, Jinyan Liu1, Xiaoyu Liang1, Xun Jin1, Jing Xie1, Le Zhang1, Degao Chen1, Roland Fiskesund1,3,4, Ke Tang5, Jingwei Ma5, Huafeng Zhang5, Wenqian Dong1, Siqi Mo1, Tianzhen Zhang1, Feiran Cheng1, Yabo Zhou1, Qingzhu Jia6, Bo Zhu6, Yan Kong7, Jun Guo7, Haizeng Zhang8, Zhuo-Wei Hu9, Xuetao Cao1, F Xiao-Feng Qin10, Bo Huang1,2,5.   

Abstract

Dynamic interaction with the immune system profoundly regulates tumor cell dormancy. However, it is unclear how immunological cues trigger cancer cell-intrinsic signaling pathways for entering into dormancy. Here, we show that IFN-β treatment induced tumor-repopulating cells (TRC) to enter dormancy through an indolamine 2,3-dioxygenase/kynurenine/aryl hydrocarbon receptor/p27-dependent (IDO/Kyn/AhR/p27-dependent) pathway. Strategies to block this metabolic circuitry did not relieve dormancy, but led to apoptosis of dormant TRCs in murine and human melanoma models. Specifically, blocking AhR redirected IFN-β signaling to STAT3 phosphorylation through both tyrosine and serine sites, which subsequently facilitated STAT3 nuclear translocation and subsequent binding to the p53 promoter in the nucleus. Upregulation of p53 in turn disrupted the pentose phosphate pathway, leading to excessive ROS production and dormant TRC death. Additionally, in melanoma patients, high expression of IFN-β correlated with tumor cell dormancy. Identification of this mechanism for controlling TRC dormancy by IFN-β provides deeper insights into cancer-immune interaction and potential new cancer immunotherapeutic modalities.

Entities:  

Keywords:  Cancer; Immunology; Melanoma; Signal transduction; Stem cells

Mesh:

Substances:

Year:  2018        PMID: 29431732      PMCID: PMC5824876          DOI: 10.1172/JCI96329

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  57 in total

1.  Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery.

Authors:  Rona M MacKie; Robin Reid; Brian Junor
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

Review 2.  Viruses and interferon: a fight for supremacy.

Authors:  Michael G Katze; Yupeng He; Michael Gale
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

Review 3.  Does tumour dormancy offer a therapeutic target?

Authors:  Paul E Goss; Ann F Chambers
Journal:  Nat Rev Cancer       Date:  2010-11-04       Impact factor: 60.716

Review 4.  Redox regulation of p53, redox effectors regulated by p53: a subtle balance.

Authors:  Agnès Maillet; Shazib Pervaiz
Journal:  Antioxid Redox Signal       Date:  2012-01-25       Impact factor: 8.401

Review 5.  Type I interferons in anticancer immunity.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Oliver Kepp; Mark J Smyth; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2015-06-01       Impact factor: 53.106

6.  An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor.

Authors:  Christiane A Opitz; Ulrike M Litzenburger; Felix Sahm; Martina Ott; Isabel Tritschler; Saskia Trump; Theresa Schumacher; Leonie Jestaedt; Dieter Schrenk; Michael Weller; Manfred Jugold; Gilles J Guillemin; Christine L Miller; Christian Lutz; Bernhard Radlwimmer; Irina Lehmann; Andreas von Deimling; Wolfgang Wick; Michael Platten
Journal:  Nature       Date:  2011-10-05       Impact factor: 49.962

7.  STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3.

Authors:  Ling Liu; Kevin M McBride; Nancy C Reich
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-26       Impact factor: 11.205

8.  Functional features of cancer stem cells in melanoma cell lines.

Authors:  Rüdiger M Zimmerer; Philippe Korn; Philippe Demougin; Andreas Kampmann; Horst Kokemüller; André M Eckardt; Nils-Claudius Gellrich; Frank Tavassol
Journal:  Cancer Cell Int       Date:  2013-08-06       Impact factor: 5.722

9.  Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells.

Authors:  Yuying Liu; Xiaoyu Liang; Xiaonan Yin; Jiadi Lv; Ke Tang; Jingwei Ma; Tiantian Ji; Huafeng Zhang; Wenqian Dong; Xun Jin; Degao Chen; Yanchun Li; Songyan Zhang; Heidi Q Xie; Bin Zhao; Tong Zhao; Jinzhi Lu; Zhuo-Wei Hu; Xuetao Cao; F Xiao-Feng Qin; Bo Huang
Journal:  Nat Commun       Date:  2017-05-10       Impact factor: 14.919

10.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

View more
  36 in total

1.  CHREBP suppresses gastric cancer progression via the cyclin D1-Rb-E2F1 pathway.

Authors:  Jianming Zhang; Jing Zhang; Zhongmao Fu; Yuan Zhang; Zai Luo; Pengshan Zhang; Yitian Xu; Chen Huang
Journal:  Cell Death Discov       Date:  2022-06-29

Review 2.  The nuclear transportation of PD-L1 and the function in tumor immunity and progression.

Authors:  Liyan Qu; Jiakang Jin; Jianan Lou; Chao Qian; Jinti Lin; Ankai Xu; Bing Liu; Man Zhang; Huimin Tao; Wei Yu
Journal:  Cancer Immunol Immunother       Date:  2022-03-05       Impact factor: 6.630

Review 3.  Basic approaches, challenges and opportunities for the discovery of small molecule anti-tumor drugs.

Authors:  Yu-Shui Ma; Ji-Bin Liu; Xiao-Li Yang; Rui Xin; Yi Shi; Dan-Dan Zhang; Hui-Min Wang; Pei-Yao Wang; Qin-Lu Lin; Wen Li; Da Fu
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

4.  Hypoxia-reprogrammed tricarboxylic acid cycle promotes the growth of human breast tumorigenic cells.

Authors:  Ke Tang; Yuandong Yu; Liyan Zhu; Pingwei Xu; Jie Chen; Jingwei Ma; Huafeng Zhang; Haiqing Fang; Weiwei Sun; Li Zhou; Keke Wei; Fei Li; Jiadi Lv; Jing Xie; Yuying Liu; Bo Huang
Journal:  Oncogene       Date:  2019-08-13       Impact factor: 9.867

Review 5.  Opposing Roles of Type I Interferons in Cancer Immunity.

Authors:  Giselle M Boukhaled; Shane Harding; David G Brooks
Journal:  Annu Rev Pathol       Date:  2020-12-02       Impact factor: 23.472

6.  Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma.

Authors:  Sébastien Corre; Nina Tardif; Nicolas Mouchet; Héloïse M Leclair; Lise Boussemart; Arthur Gautron; Laura Bachelot; Anthony Perrot; Anatoly Soshilov; Aljosja Rogiers; Florian Rambow; Erwan Dumontet; Karin Tarte; Alban Bessede; Gilles J Guillemin; Jean-Christophe Marine; Michael S Denison; David Gilot; Marie-Dominique Galibert
Journal:  Nat Commun       Date:  2018-11-14       Impact factor: 14.919

7.  Low Levels of Sox2 are required for Melanoma Tumor-Repopulating Cell Dormancy.

Authors:  Qiong Jia; Fang Yang; Wei Huang; Yao Zhang; Binghao Bao; Ke Li; Fuxiang Wei; Cunyu Zhang; Haibo Jia
Journal:  Theranostics       Date:  2019-01-01       Impact factor: 11.556

8.  The crosstalk between STAT3 and p53/RAS signaling controls cancer cell metastasis and cisplatin resistance via the Slug/MAPK/PI3K/AKT-mediated regulation of EMT and autophagy.

Authors:  Fan Liang; Chunxia Ren; Jingshu Wang; Shuoer Wang; Lina Yang; Xianghui Han; Yaping Chen; Guoqing Tong; Gong Yang
Journal:  Oncogenesis       Date:  2019-10-09       Impact factor: 7.485

9.  A Comprehensive Pan-Cancer Analysis of RBM8A Based on Data Mining.

Authors:  Nan Mei; Heyan Chen; Ni Zhao; Ye Yi; Chunli Li
Journal:  J Oncol       Date:  2021-07-06       Impact factor: 4.375

10.  Mediating the death of dormant tumor cells.

Authors:  Yuying Liu; Jiadi Lv; Bo Huang
Journal:  Mol Cell Oncol       Date:  2018-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.